A random primed expression cDNA library was constructed from the RNA of NG 108-15 cells. Pools of plasmid DNA were transfected into COS cells, which were screened for their ability to bind 'H-labeled Tyr-D-Thr-GlyPhe-Leu-Thr, a tritiated agonist for the -opioid receptor. A cDNA was isolated that encodes a 371-amino acid-residue protein presenting all the structural characteristics of receptors that interact with guanine nucleotide-binding proteins. Opioid receptors have long been described as membrane receptors of the nervous system mediating the analgesic effects of opium-derived alkaloids. Endogeneous ligands and their precursors have been characterized, and their role in response to pain and stress has been widely studied (1). Pharmacological studies have shown the existence of three subtypes of receptors, ,u (morphine), 8 (enkephalin), and K (dynorphin), the cellular inhibitory actions of which are linked to G protein activation (2). Opioid receptors are, therefore, believed to be part of the G protein-coupled receptor (GPR) family, a class of membrane-bound receptors that exhibit a seven-transmembrane-spanning domain topology and represent 80% of all known receptors (3).
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Opioid receptors have long been described as membrane receptors of the nervous system mediating the analgesic effects of opium-derived alkaloids. Endogeneous ligands and their precursors have been characterized, and their role in response to pain and stress has been widely studied (1) . Pharmacological studies have shown the existence of three subtypes of receptors, ,u (morphine), 8 (enkephalin), and K (dynorphin), the cellular inhibitory actions of which are linked to G protein activation (2) . Opioid receptors are, therefore, believed to be part of the G protein-coupled receptor (GPR) family, a class of membrane-bound receptors that exhibit a seven-transmembrane-spanning domain topology and represent 80% of all known receptors (3) .
Several attempts to clone cDNAs encoding opioid receptors have been reported. A cDNA encoding an opioid-binding protein (OBCAM) with g selectivity was isolated (4) , but the predicted protein lacks transmembrane domains, presumed necessary for signal transduction. More recently, the isolation of another cDNA was reported, which was obtained by expression cloning (5) . The deduced protein sequence displays seven putative transmembrane domains and is very similar to the human neuromedin K receptor. However, the affinity of opioid ligands for this receptor expressed in COS cells is two orders of magnitude below the expected value, and no subtype selectivity can be shown. Finally, attempts to clone opioid receptors via approaches relying on sequence similarities in the GPR family, using the PCR technology, were unsuccessful. There is, therefore, no convincing evidence that a cDNA encoding an opioid receptor has been cloned.
We report here the isolation of a cDNA encoding a 8-opioid receptorA We used a transient expression strategy where a cDNA library derived from NG 108-15 cells was screened using 3H-labeled Tyr-D-Thr-Gly-Phe-Leu-Thr (DTLET), a tritiated agonist for the 8-opioid receptor. Our pharmacological study of the cloned cDNA expressed in COS cells shows that it possesses all expected properties of a 8 receptor. A comparative analysis of the deduced protein sequence with other members of the GPR family is also presented.
MATERIALS AND METHODS Library Construction and Screening. NG 108-15 cells were provided by B. Foucaud (URA 1836, Facultd de Pharmacie, Strasbourg, France). Cells were harvested at 50% confluency, RNA was prepared by LiCl/urea precipitation (6) , and polyadenylylated RNA was purified with an oligo(dT) column (Pharmacia). The cDNA library construction in the mammalian expression vector pCDM8 has been described (7) . Plasmid DNA was prepared according to the alkaline lysis method (8) (10) . The hydrophobicity analysis was determined by the method of Kyte and Doolittle (11) with a window of 11 residues and the transmembrane-domain prediction according to Eisenberg (12) shows a single class of binding sites with an apparent Kd of 1.4 nM for both K56-transfected COS cell and NG 108-15 cell membranes. This value is similar to the described value (1.04 nM) (16) . Bm. values ranged from 3.9 to 6.4 pmol/mg of proteins, depending on the transfected membrane preparation. Considering that, on average, 10% only of the COS cells are efficiently transfected by the plasmid, the expression level of the cloned receptor could be estimated to 5 x 106 molecules per transfected cell, which is 100 times higher than the value determined for NG 108-15. Opioid receptors are highly stereoselective. Levorphanol and (-)-naloxone are known to bind to opioid receptors with high affinity, whereas their (+) enantiomers, dextrorphan and (+)-naloxone, respectively, do not, irrespective ofthe receptor subtype under study (5, 17 Fig. 2A aligned (22) with four other representative members of the family: the %2-adrenergic receptor, the neuromedin K receptor, and the rhodopsin, as well as the N-formyl peptide receptor, with which it shares the best similarity (30%o identity, 10 (Fig. 2C) . Seventeen mouse and rat sequences (preferably mouse when available except for the N-formyl peptide receptor, which is a human sequence), which displayed the best homology with K56 protein, were selected from the Swiss-Prot Data Base. As expected, the aminergic receptors and the peptidergic receptors appear as two distinct groups, and rhodopsin appears as a single sequence. K56 and the human N-formyl peptide receptor (23) form a group separate from the two main groups. In a second alignment that excluded all extra-and intracellular loops and considered the transmembrane domains only, K56 protein appeared as a group with the N-formyl peptide receptor again but closer to a group including the substance K, substance P, neuromedin K, and neuromedin B receptors (data not shown). 8 , and K, which differ in their pharmacology (17) and anatomical distribution (28) . However, biochemical characterization of opioid receptors from many groups reports a molecular mass of -60,000 Da for all three subtypes, suggesting that they could be related molecules (27) . Moreover, the similarity between the three receptor subtypes is supported by the isolation of (i) antiidiotypic monoclonal antibodies competing with both A& and 8 ligands but not competing with K ligands (29, 30) and (ii) a monoclonal antibody raised against the purified g receptor that interacts with both 1L and K receptors (31) . Low-stringency hybridization experiments with K56 cDNA as a probe may allow the isolation ofcDNAs encoding the other opioid-receptor subtypes and shed light on the question of the opioid-receptor heterogeneity.
The availability of cDNAs encoding the opioid receptors will then permit detailed studies of the signal-transduction mechanism and reveal the anatomical distribution of the mRNAs of these receptors, providing information on their expression pattern in the nervous system. This information should ultimately allow better understanding of the opioid system in nociception and analgesia and also the design of more specific therapeutic drugs.
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